CytoSorbents Corporation reported preliminary unaudited revenue results for the fourth quarter and full year of 2022. For the quarter, total revenue was approximately $9.4 million versus $10.8 million in Fourth Quarter 2021, and versus $7.4 million in pre-pandemic Fourth Quarter 2019. Fourth Quarter 2022 Product Sales were approximately $7.6 million, which rose 18% sequentially from $6.5 million in Third Quarter 2022, but were lower than the $9.7 million in Fourth Quarter 2021, which benefitted from $1.7 million in COVID-related sales. Pre-pandemic Fourth Quarter 2019 Product Sales were $6.6 million.

For the year, Preliminary unaudited 2022 Total Revenue, which includes Product Sales and Grant Revenue, was approximately $34.7 million versus $43.2 million in 2021, and $24.9 million in pre-pandemic 2019. Overall preliminary unaudited 2022 Product Sales were approximately $29.4 million versus $40.1 million in 2021, which included $0.3 million and $6.3 million in COVID-19 related Product Sales, respectively, and versus $22.8 million in pre-pandemic 2019.